The U.S. Food and Drug Administration (FDA) announced today that it has approved the use of ivacaftor (Kalydeco™) to treat people with cystic fibrosis ages 6 and older who have the R117H mutation.
Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $15 million research agreement with biopharmaceutical company Shire plc to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.
A comprehensive, updated resource to assist the cystic fibrosis community with infection prevention and control practices is now available online. “Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update” will also be published in the August print edition of Infection Control & Hospital Epidemiology, the official journal of the Society for Healthcare Epidemiology of America.
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), an affiliate of the Cystic Fibrosis Foundation, announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508.
The U.S. Food and Drug Administration announced today it has approved Kalydeco™ to treat people ages 6 and older who have one of eight additional cystic fibrosis mutations.